Log In
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Pharmacokinetics after 2-weeks Administration of CPL207280 (GPR40 agonist) in Subjects With Type 2 Diabetes (T2D)
Dear Sir or Madam,

Diabetes is classified as a chronic, systemic and metabolic disease. In diabetes pathogenesis the main factors are: impaired secretion and sensitivity to endogenous hormone - insulin. This results in elevated blood glucose level.

Diabetes is one of the biggest and still growing problem of modern medicine. Nowadays, millions of people all over the world suffer from diabetes and die each year from diabetes and its complications.

Celon Pharma SA’s product CPL207280 is a potent, specific and selective agonist of the G-protein-coupled receptor 40 (GPR40), designed for improve glucose tolerance. CPL207280 demonstrates well tolerance and safety.

We would like to invite you to participate in the study named: "A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Pharmacokinetics after 2-weeks Administration of CPL207280 (GPR40 agonist) in Subjects With Type 2 Diabetes (T2D)".

The main study objective is to determine the effect of CPL207280 on the reduction of the plasma glucose during the oral glucose tolerance test (OGTT) in patients with diabetes after 2 weeks treatment.
Celon
eCRF i Data Management
+48 666 069 834
support@biostat.com.pl
BioStat is responsible for eCRF
development, data management
and statistical service.